← Leaderboards
Wei Wei
California Institute Of Technology
$5,073,248
Attributed
$7,794,150
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,794,150 · 7
By mechanism
U01$4,710,644 · 2
R33$1,338,731 · 1
R21$1,013,614 · 2
R01$554,653 · 1
R03$176,508 · 1
Top collaborators
- James R. Heath7 shared
- Min Xue2 shared
- Raymond Yeung2 shared
- Guangrong Qin1 shared
Most similar at California Institute Of Technology
Same institution · by research overlap
- James R. Heath$23,260,811
- Athanassios Siapas$11,634,638
- John C Doyle$2,902,832
- Evgueniy Vassilev Lubenov$1,239,599
- Michael C Gurnis$8,159,482
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsTumorProgramsMalignant NeoplasmsResistanceResponseBasePharmaceutical PreparationsTranscriptomeDesignNeoplastic CellInsightPhenotypeCancer CellMetabolicGenesDrug ResistanceSamplingKineticsCellular AssayImmuneImmunotherapyProceduresDrug Development
Grant awards (18)
RarecyteFinder: A Bench-to-Bits Toolkit for Label-Free, Whole-Spectrum Analysis of Rare Disseminated Tumor Cells in Liquid and Tissue Biopsies$554,653
R01 · FY2025 · CA · contact PI
MetaboCore: Needle biopsy assay of drug sensitivity for solid tumors.$388,418
U01 · FY2025 · CA
MetaboCore: Needle biopsy assay of drug sensitivity for solid tumors.$401,113
U01 · FY2024 · CA
Liquid biopsy-based toolkits for neoantigen and cognate TCR discovery for cancer immunotherapy$442,712
R33 · FY2023 · CA · contact PI
Strategies for discerning chemotherapy response and resistance in ovarian cancer$510,364
R21 · FY2022 · CA · contact PI
Liquid biopsy-based toolkits for neoantigen and cognate TCR discovery for cancer immunotherapy$433,138
R33 · FY2022 · CA · contact PI
PRODIGE: A high-throughput tool for joint profiling of protein-DNA interactions and gene expression in single cells$228,750
R21 · FY2022 · GM · contact PI
Steady states and cellular transitions associated with carcinogenesis and tumorprogression$670,711
U01 · FY2021 · CA
Liquid biopsy-based toolkits for neoantigen and cognate TCR discovery for cancer immunotherapy$462,881
R33 · FY2021 · CA · contact PI
PRODIGE: A high-throughput tool for joint profiling of protein-DNA interactions and gene expression in single cells$274,500
R21 · FY2021 · GM · contact PI
Steady states and cellular transitions associated with carcinogenesis and tumorprogression$670,576
U01 · FY2020 · CA
Astrocyte and microglial cell state transitions in response to activation of the immune system in Alzheimer's disease$472,750
U01 · FY2020 · CA
Profiling fatty acid uptake and activity in single tumor cells$81,250
R03 · FY2020 · CA
Steady states and cellular transitions associated with carcinogenesis and tumorprogression$650,589
U01 · FY2019 · CA
Profiling fatty acid uptake and activity in single tumor cells$95,258
R03 · FY2019 · CA
Steady states and cellular transitions associated with carcinogenesis and tumorprogression$812,211
U01 · FY2018 · CA
Steady states and cellular transitions associated with carcinogenesis and tumorprogression$543,527
U01 · FY2017 · CA
Steady states and cellular transitions associated with carcinogenesis and tumor progression$100,749
U01 · FY2017 · CA